RecruitingNot ApplicableNCT07145970

Standardization of Spatial Neglect Assessment Tests

Standardization of Spatial Neglect Assessment Tests in a Francophone Population


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

210 participants

Start Date

Jan 7, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Spatial neglect is a common cognitive disorder in stroke patients, characterized by a lateralized deficit in attention and intention. This research focuses on defining norms for tests to assess spatial neglect. The norms correspond to the results obtained in a population free of any disorder that could have an impact on test performance. These results can vary in a normal, non-pathological way, with certain parameters such as age, sex, laterality or level of education. Defining these norms in healthy volunteers is therefore essential for interpreting results in patients suspected of spatial neglect, and in particular for defining pathological thresholds above which the diagnosis of spatial neglect can be retained. To answer the research question, we plan to include 210 people with no central neurological disease (stroke, epilepsy and multiple sclerosis in particular), in a single-center study in the neurovascular department of the Raymond-Poincaré hospital (Garches). The 210 subjects will be divided into 10-year age groups, from 20 to 89 years, with the recruitment of 30 participants per age group (15 men and 15 women): 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, 80-89 years.


Eligibility

Min Age: 20 YearsMax Age: 89 Years

Inclusion Criteria5

  • Healthy volunteer attending the neurovascular department of Raymond-Poincaré Hospital
  • Aged between 20 and 89 years
  • Affiliated with a health insurance scheme
  • French-speaking
  • Has freely and knowingly expressed their non-opposition

Exclusion Criteria10

  • Known history of central neurological disease: stroke (ischemic or hemorrhagic), transient ischemic attack, encephalitis, multiple sclerosis, or epilepsy.
  • Medical interview suggesting past central nervous system involvement: history of episodes such as sensorimotor deficits, dysarthria, aphasia, blurred or double vision, or positive symptoms such as visual or sensory hallucinations (e.g., paresthesias).
  • Significant visual impairment - as judged by the examiner - in near vision despite correction, or monocular blindness. Specifically, inability to distinguish the targets with gaps in the example (pre-test) of the Apples Cancellation Test.
  • Abnormal neurological examination:
  • National Institutes of Health Stroke Scale (NIHSS) score \> 0
  • Pyramidal reflex syndrome (hyperactive deep tendon reflexes with extended reflexogenic zones and spread).
  • Use of substances (alcohol or drugs) within 24 hours prior to the assessment.
  • Presence of cognitive or psychiatric disorders, assessed during the inclusion interview and neurological examination, at the examiner's discretion.
  • Language barrier or aphasia, assessed during the inclusion interview and neurological examination, at the examiner's discretion.
  • Participant under legal protection (guardianship, curatorship, or legal safeguard).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNeuropsychological assessment tests for spatial neglect

Standardized administration of four paper-and-pencil tests designed to assess different forms of spatial neglect: * Apples Cancellation Test (Birmingham Cognitive Screen) for egocentric and allocentric neglect, * Simplified Comb and Razor Test for personal and motor neglect, * Line Bisection Test (30 cm ruler, blind version) for tactile neglect, * Dot Test for visual exploration. The purpose is to establish normative reference scores in healthy French-speaking adults according to age, sex, and professional qualification. No therapeutic intervention or patient population is involved.


Locations(1)

CHU Raymond Poincarré

Garche, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07145970


Related Trials